^
Association details:
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
New
Title:

Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer

Excerpt:
This case report presents a 58-year-old man with HER2-amplified mCRC and a KRAS G12D mutation...He subsequently derived a clinical benefit with metastatic lung disease regression on trastuzumab emtansine (T-DM1). He eventually experienced disease progression in the liver after 6 every-3-week cycles.
DOI:
10.6004/jnccn.2019.7371